BMY stock was trading at $74.21 as of 11:21 A.M. EDT.

Bristol Myers Squibb (NYSE:BMY) looked back at the phase 3 open-label extension (OLE) study and found that more than 92% of patients who took the MS drug Zeposia had a serologic response to the COVID-19 vaccine.

In the current OLE part of the phase 3 study, called DAYBREAK, it was found that 137 out of 148 people with relapsed MS showed a serological response after being immunized.

The company said in a news release on Wednesday that after a full COVID-19 mRNA or non-mRNA vaccination, seroconversion was seen in 100% (39/39) of patients who had already been exposed to COVID-19, the company said in a news release.

According to study scientist Bruce Cree, “These insights are of therapeutic value for physicians treating multiple sclerosis because they give a clearer knowledge of how COVID-19 infections and vaccines interact with Zeposia medication.”

The company also said that 10% (15/148) of people who got the COVID-19 vaccine had side effects, but none of them were serious. Also, BMY said that the phase 3 DAYBREAK OLE research showed that 68% of the people who took part had not relapsed and that the adjusted annualized relapse rate (ARR) was 0.099 at up to 74 months of therapy.

in the presence representing the meeting on behalf of ECTRIMS, the European Committee for Multiple Sclerosis Treatment and Research was established. its 38th Congress in Amsterdam, Bristol-Myers will present 13 abstracts, which will include the data. 

BMY stock outlook

Following last night’s earnings announcement, Bristol-Myers shares were marked 1.5% higher in early Wednesday trading to trade at $73.84, bringing the stock’s six-month drop to about 2.3%. Sotyktu, the first new treatment for individuals with moderate-to-severe plaque psoriasis in more than ten years, was given federal approval last month by Bristol Myers. It is expected to compete for the $2.3 billion market that Otezla, a drug made by Amgen, already has.

BMY Stock Rises As FDA Reviews Cardiac Medication Camzyos For Broader Usage